Saltar a la navegació principal
Saltar a la cerca
Vés al contingut principal
Portal de Recerca de la Universitat Autònoma de Barcelona Inici
Ajuda i PMF
Català
Español
English
Inici
Perfils
Unitats de recerca
Projectes
Producció científica
Conjunts de dades
Tesis i Treballs supervisats
Cerca per experiència, nom o afiliació
EVALUACION IN VITRO E IN VIVO DE NUEVOS NANOPORTADORES PARA ADMINISTRACION INTRANASAL EN EL TRATAMIENTO Y DIAGNOSTICO DE ENFERMEDADES CEREBRALES.
Lorenzo Rivera, Julia
(PI)
David Montpeyó García-Moreno
(Col.laborador/a)
Alfonso Triguero, Paula
(Col.laborador/a)
Sarle Valles, Pau
(Col.laborador/a)
Pradas Gracia, Eddi
(Col.laborador/a)
Jiménez Agular, Rafael
(Col.laborador/a)
Mulero Acevedo, Marta
(Col.laborador/a)
Rodriguez Calado, Sergi
(Col.laborador/a)
Departament de Bioquímica i de Biologia Molecular
Institut de Recerca Hospital Universitari Vall d'Hebron
Universitat Autònoma de Barcelona (UAB)
Institut Català de Nanociència i Nanotecnologia (ICN2)
Informació general
Fingerprint
Producció científica
(1)
Fingerprint
Explora els temes de recerca tractats en aquest projecte. Les etiquetes es generen en funció dels ajuts rebuts. Juntes formen un fingerprint únic.
Ordenar per
Ponderació
Alfabèticament
Keyphrases
Glioblastoma Therapy
83%
Nanoformulation
83%
Nanotherapeutics
83%
Platinum-based
83%
Platinum Drugs
83%
Doxorubicin
83%
Magneto-fluorescent Nanoparticles
83%
Nanoparticles
83%
Colorectal Cancer
83%
Prodrug
55%
Cetuximab
55%
Cytotoxicity
55%
Antitumoral
55%
Blood-brain Barrier
55%
Temozolomide
55%
Platinum Complexes
55%
Therapeutic Effect
27%
Current Therapies
27%
Platinum(IV)
27%
Alkylating Agents
27%
Glioblastoma
27%
Neurotoxicity
27%
Complex Action
27%
Dismal Prognosis
27%
Nanosystems
27%
Nanoparticle Surface
27%
Intracellular Accumulation
27%
Passive Diffusion
27%
Standard of Care
27%
Targeted Agents
27%
Anti-EGFR
27%
Tumor Cells
27%
HCT-116 Cell Line
27%
Median Survival
27%
Cancer Cells
27%
Systemic Toxicity
27%
Radiotherapy
27%
Colorectal Cancer Cells
27%
Long-term Treatment
27%
Intrinsic Resistance
27%
Chemotherapy
27%
Glioblastoma multiforme
27%
Cancer Cell Lines
27%
Anticancer Activity
27%
Concomitant Treatment
27%
Reduced Toxicity
27%
Malignancy
27%
Commercially Available
27%
New Targets
27%
Carbonic Anhydrase IX
27%
Surface Modification
27%
Drug Stability
27%
Chemoradiotherapy
27%
Magnetofluorescent
27%
Cellular Uptake
27%
Anticancer Drugs
27%
Surgical Resection
27%
Oral Administration
27%
Multi-action
27%
Brain Tumor
27%
Non-invasive Treatment
27%
Cancer Chemotherapy
27%
Ofloxacin
27%
Nanomedicine
27%
Platinum Anticancer Drugs
27%
Pt-based Drugs
27%
Nanocarriers
27%
Acetazolamide
27%
Still Face
27%
Acquired Resistance
27%
Enteric Coating
27%
Lipophilicity
27%
Eudragit
27%
Drug Loading Capacity
27%
Pharmacology, Toxicology and Pharmaceutical Science
Nanoparticle
100%
Glioblastoma
83%
Colorectal Carcinoma
83%
Doxorubicin
62%
Cetuximab
41%
Cytotoxicity
41%
Anticarcinogen
33%
Temozolomide
33%
Chemotherapy
33%
Prodrug
33%
Blood-Brain Barrier
33%
Platinum Complex
33%
Nanocarrier
20%
Eudragit
20%
Enteric Coating
20%
Ofloxacin
20%
Epidermal Growth Factor Receptor
20%
Acetazolamide
20%
Neoplasm
16%
Nanomedicine
16%
Lipophilicity
16%
Therapeutic Effect
16%
Antiinfective Agent
16%
Intracranial Tumor
16%
Side Effect
16%
Chemoradiation Therapy
16%
Alkylating Agent
16%
Malignant Neoplasm
16%
Neurotoxicity
16%
Medicine and Dentistry
Glioblastoma
83%
Blood Brain Barrier
33%
Platinum Complex
33%
Anticarcinogen
33%
Temozolomide
33%
Prodrug
33%
Intracranial Tumor
16%
Therapy Effect
16%
Radiation Therapy
16%
Chemotherapy
16%
Cancer
16%
Cancer Cell
16%
Cancer Chemotherapy
16%
Tumor Cell
16%
Antiinfective Agent
16%
Chemoradiotherapy
16%
Antineoplastic Activity
16%
Surgery
16%
Side Effect
16%
Alkylating Antineoplastic Agent
16%
Nanoparticle
16%
Neurotoxicity
16%
Nanomedicine
16%